States prep for loss of ACA

Several states are working on their own healthcare plans to preserve some coverage and provisions of the Affordable Care Act as the healthcare law makes its way through an appeals court and faces the real possibility of being overturned, The Wall Street Journal reported.

In the absence of a Trump administration healthcare plan to replace the ACA, a huge gap in insurance could be in the future. The ACA is facing its biggest legal challenge to date after a Republican-led lawsuit sought to overturn it and a federal judge declared the entire law unconstitutional last year. While Democrats have appealed the decision, the ACA remains the law of the land.

Some lawmakers in a handful of states, including Louisiana, Nevada, New Mexico and California, have approved legislation or are reviewing action to deal with the possibility that the ACA could be tossed out soon, the WSJ reported. The plans include providing subsidies to high-cost patients, coverage gap solutions and rules to prevent people from being denied coverage.

Part of the motivation by these lawmakers to provide assurance that their constituents would be able to find health insurance in the case that the ACA were to be tossed are tight re-election campaigns, according to the WSJ.

Under the ACA provisions, people with pre-existing conditions cannot be denied health insurance coverage or be forced to pay more for their plan. Those protections would go away if the ACA is invalidated, exposing up to 54 million Americans with a pre-existing condition, according to one estimate.

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.